Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...
Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...
Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback